Remission of Persistent Negative Symptoms and Psychosocial Consequences by Combined Clozapine and Cariprazine Treatment in a Patient With Long-Standing Treatment-Resistant Schizoaffective Disorder

Bibliographic Details
Title: Remission of Persistent Negative Symptoms and Psychosocial Consequences by Combined Clozapine and Cariprazine Treatment in a Patient With Long-Standing Treatment-Resistant Schizoaffective Disorder
Authors: Mats Bogren, Monica Soltesz, Stephan Hjorth
Source: Frontiers in Psychiatry, Vol 13 (2022)
Publisher Information: Frontiers Media S.A., 2022.
Publication Year: 2022
Collection: LCC:Psychiatry
Subject Terms: Antipsychotic polypharmacy, negative symptoms (schizophrenia), cognitive symptoms of schizophrenia, psychosocial symptoms, quality-of-life, reward system, Psychiatry, RC435-571
More Details: This patient case report describes a 45-year old white unmarried man with disability pension due to schizoaffective disorder, diagnosed at the age of 24. He lives in an apartment and has housing support. Retrospectively, the patient displayed prodromal markers of a disorder within the schizophrenia spectrum many years before the onset of frank psychosis, indeed since childhood. Over the years several symptoms and signs across schizophrenia domains have been manifest: positive, negative, cognitive, and affective, among which the negative and affective symptoms and signs were the earliest to appear. While the positive, disorganized, and catatonic symptoms responded to treatment – when duly tested and complied with – the negative and affective symptoms have been notoriously difficult to handle. We now report on the successful introduction of cariprazine (CAR) to his ongoing clozapine (CLZ) medication, the result of which has been a near-complete remission of his persistent negative and psychosocial issues. We interpret this remarkable alleviation of the patient's disease – and concomitant improvement of his quality of life – in terms of neuroreceptor target complementarity between CLZ and CAR, with particular emphasis on the contributions from the D3 and D2 receptor partial agonist components of the latter agent.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1664-0640
Relation: https://www.frontiersin.org/articles/10.3389/fpsyt.2022.887547/full; https://doaj.org/toc/1664-0640
DOI: 10.3389/fpsyt.2022.887547
Access URL: https://doaj.org/article/c7b7ffefca254ab898e890a0b0659eb9
Accession Number: edsdoj.7b7ffefca254ab898e890a0b0659eb9
Database: Directory of Open Access Journals
More Details
ISSN:16640640
DOI:10.3389/fpsyt.2022.887547
Published in:Frontiers in Psychiatry
Language:English